Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA2 | P00918 | 5/20 | 0.65 |
| ▸ | CA6 | P23280 | 3/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5818974 | 0.81 | CA2 (0.50) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL38660050 | 0.81 | CA1 (0.68) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL2475835 | 0.81 | CA1 (0.68) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL8686749 | 0.79 | CA1 (0.65) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL30630011 | 0.79 | CA2 (1.00) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL344271 | 0.79 | CA2 (1.00) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL122413 | 0.77 | CA1 (0.62) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL10415325 | 0.77 | CA2 (0.95) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL8071 | 0.77 | CA1 (0.62) | CA1CA2CA6CA4PLCG1 | |
| SCHEMBL1542687 | 0.77 | CA1 (0.62) | CA1CA2CA6CA4PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605310-B | Synthesis method of aza five-membered ring and three-membered ring carboxylic ester derivative and salt thereof | 都创(上海)医药科技股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20220227773-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-07-21 | — | — | US | claimed |
| CN-112010859-B | Fused ring compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-07-19 | — | — | CN | claimed |
| WO-2020239073-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2020-12-03 | — | — | WO | claimed |
| CN-112010859-A | Fused ring compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-12-01 | — | — | CN | claimed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | claimed |
| US-20180002367-A1 | Phosphorodiamidate Backbone Linkage for Oligonucleotides | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-01-04 | — | — | US | claimed |
| WO-2016187028-A1 | HETEROARYL COMPOUNDS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-24 | — | — | WO | claimed |
| US-8492390-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2013-07-23 | — | — | US | claimed |
| US-8084458-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2011-12-27 | — | — | US | claimed |
| US-20020086884-A1 | Anticancer agents based on regulation of protein prenylation | ARIZONA BIOMEDICAL RESEARCH COMMISSION | 2002-07-04 | — | — | US | claimed |
| WO-2002034247-A2 | ANTICANCER AGENTS BASED ON REGULATION OF PROTEIN PRENYLATION | THE ARIZONA DISEASE CONTROL RESEARCH COMMISSION (US) | 2002-05-02 | — | — | WO | claimed |
| JP-3187838-B2 | — | — | 2001-07-16 | — | — | JP | claimed |
| EP-0737195-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018131-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1995-07-06 | — | — | WO | claimed |
| CN-1092776-A | 2-(9-Fluorenone base) carbapeneme intermediate | MERCK & CO INC (US) | 1994-09-28 | — | — | CN | claimed |
| US-4837307-A | [1,1'-biphenyl]compounds having a 2,2'-(alkyl)bridge and a 3-yl(substituted)methyl substituent | FMC CORPORATION (US) | 1989-06-06 | — | — | US | claimed |
| US-4680310-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-07-14 | — | — | US | claimed |
| US-4668792-A | Intermediates to insecticidal [1,1'-biphenyl]-3-ylmethyl esters | FMC CORPORATION (US) | 1987-05-26 | — | — | US | claimed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002367-A1 | Phosphorodiamidate Backbone Linkage for Oligonucleotides | RNGTT, NCL, NOP56 | CA1 3932/4885CA2 4079/4885CA6 3205/4885 |
| US-20220227773-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC18A2, SLC6A3, SLC18A3 | CA1 3998/4885CA2 4356/4885CA6 4755/4885 |
| US-20020086884-A1 | Anticancer agents based on regulation of protein prenylation | ARHGDIB, ARHGDIA, RHOA | CA1 4208/4885CA2 4143/4885CA6 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.